Irreversible ototoxicity associated with zalcitabineMONTE, S; FENWICK, J. D; MONTEIRO, E. F et al.International journal of STD & AIDS. 1997, Vol 8, Num 3, pp 201-202, issn 0956-4624Article

Survival effects of ZDV, ddI, and ddC in patients with CD4 ≤50 cells/mm³KAZEM KAZEMPOUR; KAMMERMAN, L. A; FARR, S. S et al.Journal of acquired immune deficiency syndromes and human retrovirology. 1995, Vol 10, pp S97-S106, issn 1077-9450, SUP2Conference Paper

A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patientsROCA, B; OLMOS, P; MINGUEZ, C et al.Scandinavian journal of infectious diseases. 1998, Vol 30, Num 4, pp 426-428, issn 0036-5548Article

Cytosine deoxyribonucleoside anti-HIV analogues: a small chemical substitution allows relevant activitiesSCAGLIONE, Francesco; BERRINO, Liberato.International journal of antimicrobial agents (Print). 2012, Vol 39, Num 6, pp 458-463, issn 0924-8579, 6 p.Article

Transdermal penetration of zalcitabine, lamivudine and synthesised N-acyl lamivudine estersGERBERA, Minja; BREYTENBACH, Jaco C; DU PLESSIS, Jeanetta et al.International journal of pharmaceutics. 2008, Vol 351, Num 1-2, pp 186-193, issn 0378-5173, 8 p.Article

Insights from monitoring the CPCRA didanosine/zalcitabine trialFLEMING, T. R; NEATON, J. D; GOLDMAN, A et al.Journal of acquired immune deficiency syndromes and human retrovirology. 1995, Vol 10, pp S9-S18, issn 1077-9450, SUP2Conference Paper

Pharmacologic therapy for human immunodeficiency virus infection : a reviewNEUZIL, K. M.The American journal of the medical sciences. 1994, Vol 307, Num 5, pp 368-373, issn 0002-9629Article

Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutationsIZOPET, J; SAILLER, L; SANDRES, K et al.Journal of medical virology. 1999, Vol 57, Num 2, pp 163-168, issn 0146-6615Article

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeterREVICKI, D. A; MOYLE, G; STELLBRINK, H.-J et al.AIDS (London). 1999, Vol 13, Num 7, pp 851-858, issn 0269-9370Article

Antiviral effect of double and triple drug combinations amongst HIV-infected adults : lessons from the implementation of viral load-driven antiretroviral therapyHOGG, R. S; RHONE, S. A; YIP, B et al.AIDS (London). 1998, Vol 12, Num 3, pp 279-284, issn 0269-9370Article

Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitroHOGGARD, P. G; SALES, S. D; KEWN, S et al.Antiviral chemistry & chemotherapy. 2000, Vol 11, Num 6, pp 353-358, issn 0956-3202Article

Exonuclease Removal of Dideoxycytidine (Zalcitabine) by the Human Mitochondrial DNA PolymeraseHANES, Jeremiah W; JOHNSON, Kenneth A.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 1, pp 253-258, issn 0066-4804, 6 p.Article

Inactivations of p16^INK4a-α, p16^INKa-β and p15^INK4b genes in 2', 3'-dideoxycytidine- and 1,3-butadiene-induced murine lymphomasZHUANG, S.-M; SCHIPPERT, A; HAUGEN-STRANO, A et al.Oncogene (Basingstoke). 1998, Vol 16, Num 6, pp 803-808, issn 0950-9232Article

A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complexGRIES, J.-M; TROCONIZ, I. F; VEROTTA, D et al.Clinical pharmacology and therapeutics. 1997, Vol 61, Num 1, pp 70-82, issn 0009-9236Article

Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival : An observational studyVAN LEEUWEN, R; BONSEL, G. J; REISS, P et al.The Journal of infectious diseases. 1997, Vol 175, Num 6, pp 1344-1351, issn 0022-1899Article

Zalcitabine : An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infectionADKINS, J. C; PETERS, D. H; FAULDS, D et al.Drugs (Basel). 1997, Vol 53, Num 6, pp 1054-1080, issn 0012-6667Article

Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of Interferon-α_2a in patients with HIVFISCHL, M. A; RICHMAN, D. D; SAAG, M et al.Journal of acquired immune deficiency syndromes and human retrovirology. 1997, Vol 16, Num 4, pp 247-253, issn 1077-9450Article

Separate and joint modeling of longitudinal and event time data using standard computer packagesGUO, Xu; CARLIN, Bradley P.The American statistician. 2004, Vol 58, Num 1, pp 16-24, issn 0003-1305, 9 p.Article

Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection : meta-analyses of the randomised evidenceLancet (British edition). 1999, Vol 353, Num 9169, pp 2014-2025, issn 0140-6736Article

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in SpainGOMEZ-CANO, M; RUBIO, A; LEAL, M et al.AIDS (London). 1998, Vol 12, Num 9, pp 1015-1020, issn 0269-9370Article

Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2',3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina)TUNTLAND, T; NOSBISCH, C; UNADKAT, J. D et al.Journal of antimicrobial chemotherapy (Print). 1997, Vol 40, Num 5, pp 687-693, issn 0305-7453Article

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapyVANHOVE, G. F; KASTRISSIOS, H; GRIES, J.-M et al.Antimicrobial agents and chemotherapy. 1997, Vol 41, Num 11, pp 2428-2432, issn 0066-4804Article

Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV diseaseMONTANER, J. S. G; HOGG, R; SROUR, L. F et al.Journal of acquired immune deficiency syndromes and human retrovirology. 1996, Vol 13, Num 5, pp 422-426, issn 1077-9450Article

Improved combined solid-phase extraction-RIA method for quantifying zalcitabine in plasmaKASTRISSIOS, H; NAKANO, M; BURTON, P et al.Clinical chemistry (Baltimore, Md.). 1996, Vol 42, Num 3, pp 465-466, issn 0009-9147Article

Solid-phase extraction combined with radioimmunoassay for measurement of zalcitabine (2',3'-dideoxycytidine) in plasma and serumROBERTS, W. L; BUCKLEY, T. J; RAINEY, P. M et al.Clinical chemistry (Baltimore, Md.). 1994, Vol 40, Num 2, pp 211-215, issn 0009-9147Conference Paper